iTBS for Increased Appetite Induced by Antipsychotics
ConditionSchizophrenia
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-40
SponsorCentral South University
About this trial
Antipsychotics are prone to cause metabolic side effects, including weight gain, hyperglycemia, insulin resistance, hyperlipidemia and so on, leading to a 2-3 times higher risk of death in patients with schizophrenia compared to healthy people. Conventional high-frequency rTMS have been used to treat people with obesity and showed certain effectiveness. However, studies involving schizophrenia patients and intermittent theta burst (iTBS) mode are rarely seen. The goal of this clinical trial is to evaluate the efficacy and safety of iTBS on ameliorating increased appetite induced by antipsychotics in people with schizophrenia.
Eligibility criteria
Qualifiers
Age between 18-40 years old;
Meeting the diagnostic criteria for schizophrenia in DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition);
BMI ≥ 25kg/m 2 or over 10% weight gain after taking antipsychotics in the last year;
Not receiving TMS therapy in the past month;
Disqualifiers
Other severe mental illnesses, mental retardation, dementia and severe cognitive impairment according to diagnostic criteria of ICD-10 or DSM-5;
Abnormal brain structure or function owing to any major physical disease, neurological disease, traumatic brain injury, etc.;
Metallic implants, pacemakers, epilepsy history or other contraindications of TMS;
Suicidal thoughts or behaviors;
Trial design
Treatments tested in this trial
- Active iTBS
- Sham iTBS
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov